GleamWall
中文EN

ACRV Acrivon Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$14.55M$13.84M$15.17M$14.75M$13.65M$16.18M$15.41M$18.63M
SG&A expense$3.97M$4.82M$4.74M$5.37M$6.04M$6.47M$6.25M$6.32M
Operating income-$18.52M-$18.67M-$19.90M-$20.12M-$19.69M-$22.65M-$21.66M-$24.95M
Net income-$17.90M-$17.96M-$19.04M-$18.98M-$18.23M-$21.01M-$19.68M-$22.83M
EBITDA-$18.12M-$18.27M-$19.52M-$19.75M-$19.39M-$22.35M-$21.35M-$24.65M
EPS (basic)-0.42-0.43-0.49—-0.47-0.55-0.51—
EPS (diluted)-0.42-0.43-0.49—-0.47-0.55-0.51—
Weighted avg. shares (diluted)42.88M41.84M38.72M—38.56M38.46M38.35M—
Balance sheet
Cash & equivalents$47.53M$41.42M$34.06M$41.50M$35.41M$41.90M$39.15M$39.82M
Short-term investments$30.22M$48.54M$63.67M$77.08M$93.85M$95.53M$110.48M$139.66M
Current assets$79.08M$91.49M$99.22M$120.44M$130.36M$138.41M$151.33M$181.63M
PP&E, net$3.83M$4.25M$4.65M$4.89M$5.19M$5.07M$4.68M$4.47M
Total assets$85.75M$99.09M$107.83M$129.72M$145.30M$158.58M$176.35M$196.59M
Current liabilities$14.28M$11.45M$11.05M$15.66M$14.89M$13.43M$13.55M$17.21M
Total liabilities$14.97M$12.43M$12.32M$17.20M$16.70M$15.55M$15.96M$19.80M
Shareholders' equity$70.77M$86.67M$95.52M$112.52M$128.60M$143.04M$160.39M$176.79M
Shares outstanding42.91M42.85M38.75M31.65M31.55M31.45M31.35M31.23M
Cash flow statement
Operating cash flow-$12.38M-$14.86M-$20.54M-$15.24M-$12.28M-$16.61M-$19.54M-$17.36M
Capital expenditure$0$87,000$14,000$219,000$899,000$493,000$58,000$827,000
Free cash flow-$12.38M-$14.95M-$20.55M-$15.46M-$13.18M-$17.10M-$19.59M-$18.19M
Investing cash flow$18.50M$14.95M$13.13M$21.52M$5.91M$19.45M$19.21M$14.41M
Financing cash flow$0$7.27M-$33,000-$192,000-$117,000-$97,000-$343,000-$647,000
Depreciation & amortization$400,000$400,000$383,000$361,000$300,000$300,000$311,000$303,000
Stock-based compensation$2.00M$2.21M$2.18M$3.09M$3.91M$3.93M$3.79M$3.71M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.